INM
InMed Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · CA
$1.77
+5.36%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.81
From 52W high−4.32%
Volume90504.00
Market cap$9.72M
P/E (TTM)—
P/S (TTM)0.0x
Div yield—
Key dataNov 4, 2026
Open
$1.81
From 52W high
−4.32%
Volume
90504.00
Market cap
$9.72M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
112.2x
P/E (TTM)
—
RSI (14)
75.9
MomentumView details →
1D Return
+5.36%
YTD Return
+59.42%
SummaryUpdated Sep 1, 2026
InMed Pharmaceuticals Inc. (NASDAQ:INM) is a clinical-stage pharmaceutical company founded in 1981 and headquartered in Vancouver, Canada. Originally incorporated as Cannabis Technologies Inc., the company changed its name to InMed Pharmaceuticals in October 2014 and went public in May 2014. InMed focuses on developing cannabinoid-based therapies for rare diseases and has evolved from early-stage research into clinical trials, with its lead product candidate currently in Phase 2 clinical development for a rare skin condition.
Similar companies
Latest newsMore news →
InMed Pharmaceuticals reported financial results for its first quarter of fiscal 2027, ended September 30, 2026.1d agoInMed Pharmaceuticals announced a proposed consolidation of its common shares at a ratio of one post-consolidation share for every ten pre-consolidation shares, subject to shareholder approval at its November 4, 2026 meeting.2d ago